Jefferies analyst Oren Livnat boosted his price target on Buy-rated AcelRx Pharmaceuticals (NASDAQ: ACRX) from $13 to $14 following Q2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE